Document:

EXHIBIT
      10.9

    

    ASSIGNMENT
      OF EMPLOYMENT AGREEMENT

    

    ASSIGNMENT
      OF EMPLOYMENT AGREEMENT (this
      “Agreement”),
      dated
      as of September 17, 2007, by and among Trans-Pharma Corporation, a Nevada
      corporation (“Trans-Pharma”),
      Transdel Pharmaceuticals, Inc., a Delaware corporation (“Transdel”),
      and
      Juliet Singh, PhD (“Executive”).

    

    WHEREAS,
      Trans-Pharma and Executive have entered into that certain Employment Agreement,
      dated as of June 27, 2007 (the “Employment
      Agreement”);

    

    WHEREAS,
      Trans-Pharma and Executive wish to assign Trans-Pharma’s obligations, right,
      title, interest in, to and under the Employment Agreement to Transdel and
      Transdel agrees to assume and accept such assignments and Executive consents
      to
      such assignment.

    

    NOW
      THEREFORE, Trans-Pharma, Transdel and Executive agree as follows:

    

    1. Assignment
      and Assumption.
      Trans-Pharma does hereby assign (the “Assignment”)
      unto
      Transdel all of its obligations, right, title, interest in, to and under the
      Employment Agreement. Each of the undersigned consents to the
      Assignment.

    

    2.  Ratification.
      Except
      as assigned hereby, nothing herein contained shall otherwise modify, reduce,
      amend or otherwise supplement the terms and provisions of the Employment
      Agreement, which shall remain in full force and effect in accordance with its
      terms.

    

    3. Governing
      Law.
      This
      Agreement shall be governed by, and be construed in accordance with, the laws
      of
      the State of California. 

    

    4. Counterparts.
      This
      Agreement may be executed in one or more counterparts and by the parties hereto
      in separate counterparts, each of which when executed shall be deemed to be
      an
      original but both of which together shall constitute one and the same
      Amendment.

    

    [SIGNATURE
      PAGE FOLLOWS]

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    IN
      WITNESS WHEREOF, Trans-Pharma, Transdel, and Executive have executed this
      Agreement as of the date first written above.

    

    
      	
              Trans-Pharma
                Corporation

            
	 	 
	
              By:
                

            	
              /s/
                Juliet Singh, Ph.D.

            
	 	
              Name:
                Juliet Singh, PhD

            
	 	
              Title:  
                Chief Executive Officer

            
	 	 
	
              Transdel
                Pharmaceuticals, Inc.

            
	 	 
	
              By:
                

            	
              /s/
                John T. Lomoro

            
	 	
              Name:
                John T. Lomoro

            
	 	
              Title:  
                Chief Financial Officer

            
	 	 
	
              Executive:

            
	 
	
              /s/
                Juliet Singh, Ph.D.

            
	
              Juliet
                Singh, PhDEXHIBIT
      10.10

     

    EMPLOYMENT
      AGREEMENT

     

    THIS
      EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of June 27, 2007
      (“Effective Date”), by and between Trans-Pharma Corporation (“Company”) and Dr.
      Juliet Singh (“Executive”).

     

    PRELIMINARY
      STATEMENT

     

    A.           
      WHEREAS, The Company and the Executive desire to enter into this Agreement
      to
      provide for Executive’s employment by the Company, upon the terms and conditions
      set forth herein.

     

    The
      parties hereby agree as follows:

     

    1.            
      Duties.

     

    1.1.         
      Position. 
      Executive shall serve as Chief Executive Officer and President, and serve on
      the
      Company Board of Directors, and shall have the duties and responsibilities
      incident to such position and such other duties as may be determined in
      consultation with the Company’s Board of Directors (“Board of Directors”).
      Executive shall perform faithfully, cooperatively and diligently all of her
      job
      duties and responsibilities and agrees to and shall devote her full time,
      attention and effort to the business of the Company and other assignments as
      directed by the Company’s Board of Directors. The Executive will report directly
      to the Board of Directors

     

    1.2.         
      Best
      Efforts. 
      Executive will expend her best efforts on behalf of the Company in connection
      with her employment and will abide by all policies and decisions made by
      Company, as well as all applicable federal, state and local laws, regulations
      or
      ordinances.

     

    2.            
      Employment
      Term. 
      The term of Executive’s employment under this Agreement shall commence as of the
      Effective Date and shall continue until terminated by either the Executive
      or
      the Company (“Term”).

     

    3.            
      Compensation.

     

    3.1.         
      Base
      Salary. 
      As compensation for Executive’s performance of her duties hereunder, Company
      shall pay to Executive an initial base salary of One Hundred and Ninety-Five
      Thousand Dollars ($195,000), starting on the Effective Date hereof, (“Annual
      Base Salary”), payable in accordance with the normal payroll practices of
      Company, less required deductions for state and federal withholding tax, social
      security and all other employment taxes and payroll deductions. 
Executive’s Annual Base Salary shall be eligible for an increase based upon the
      recommendation of the Board of Directors.

     

    3.2.         
      Annual
      Bonus and Equity Plan. 
      The Executive shall be eligible to receive an annual bonus and participate
      in
      the Company’s Equity Plan, which basis will be determined by mutual agreement
      between the Executive and the Board of Directors. 

     

    4.            
      Health
      and Welfare Benefit Plans. 
      The Executive and/or the Executive’s family, as the case may be, shall be
      eligible for participation in and shall receive all benefits under health and
      welfare benefit plans, practices, policies and programs provided by the Company
      (including, without limitation, medical prescription, dental disability, salary
      continuance, employee life, group life, accidental death and travel accident
      insurance plans and programs) to the extent generally applicable to employees
      of
      the Company.

     

    
      
         

        
        

      

      
        -1-

        
          

        

      

      
        
        

      

    

    5.            
      Customary
      Benefits. 
      Executive shall be entitled to all customary and usual fringe benefits and
      shall
      be entitled to participate in all savings and retirement plans, practices,
      policies and programs generally applicable to employees of the Company that
      are
      in effect during the Employment Term, subject to the terms and conditions of
      Company’s benefit plan documents, as applicable.  

     

    6.            
      Business
      Expenses. 
      Executive shall be entitled to receive prompt reimbursement for all reasonable,
      out-of-pocket business expenses incurred in the performance of her duties on
      behalf of Company.  

     

    7.            
      Vacation. 
      Executive shall be entitled to paid vacation, personal and sick days each
      calendar year, in accordance with the Company’s plans, policies and programs
      then in effect. 

     

    8.             Indemnification.
      In
      connection with the execution of the Agreement, the Company will also enter
      into
      a customary indemnification agreement with Executive.

     

    9.            Termination.
      The
      Executive’s employment hereunder may be terminated under the following
      circumstances (without impairing the Executive’s rights under benefit plans,
      arrangements and Company policies and procedures).

     

    9.1 Termination
      upon Death or Permanent Disability.
      The
      Executive’s Term of employment shall automatically terminate in the event of the
      death or permanent disability of Executive. For purposes of this Agreement,
      “permanent disability” shall mean the inability to perform services hereunder
      for a period of six consecutive months.

     

    9.2. Termination
      by Company for Cause.
      The
      Company shall have the option to terminate the Term (a) for cause in the event
      the Executive engages in grossly negligent conduct or willful misconduct in
      connection with the execution of her duties hereunder which materially and
      adversely affect the Company, after written notice by the Company to the
      Executive of the specific nonperformance of her duties hereunder, provided
      the
      nonperformance continues uncorrected for a period of thirty days after written
      notice thereof by the Company to the Executive specifically identifying the
      manner in which the Company believes the Executive has not performed her duties.
      For purposes of this Section 9.2, no act, or failure to act, on the Executive’s
      part shall be considered “willful” unless done, or omitted to be done, by her
      not in good faith and without reasonable belief that her act or omission was
      in
      the best interests of the Company.

     

    9.3. Severance.
      If the
      Company terminates Executive’s employment other than for cause pursuant to
      Section 9.2, Executive shall be entitled to receive a continuation of her then
      Annual Base Salary plus health care insurance coverage for a period of one
      (1)
      year from said date of termination, with such base salary continuation to be
      at
      the rate set forth in Section 3.1, or, if greater, the rate of the Executive’s
      current Annual Base Salary at the date of Termination.

     

    Nothing
      herein shall derogate from the Executive’s rights under employee benefit plans,
      programs and arrangements under applicable law.

     

    9.4.
       Constructive
      Discharge.
       Any
      significant reduction or adverse change in the nature or scope of the
      Executive’s authority, duties, status or position contemplated by Section 1.1
      hereof, including an involuntary relocation, or a reduction in the base salary
      and/or benefits of the Executive from those provided for in Sections 4 and
      5
      hereof as they may from time to time be in effect, will be the basis for the
      Executive’s termination of this Agreement by giving at least thirty days prior
      notice to the Company, and in such event the termination will be treated as
      a
      termination by the Company without cause under Section 9.3.

     

    
      
         

        
        

      

      
        -2-

        
          

        

      

      
        
        

      

    

    9.5. Benefits
      upon Termination for Cause or Voluntary Termination by Executive.
      In the
      event the Company properly terminates Executive’s employment under this
      Agreement for cause pursuant to Section 9.2 or Executive voluntarily resigns
      from her employment during the Term: 

     

    (a)
      base
      salary shall be prorated as of the date of termination and said prorated amount
      shall be paid to Executive, 

     

    (b)
      all
      stock options or stock appreciation rights granted to Executive shall be
      governed by the instruments granting such rights; and

     

    (c)
      the
      Company shall (i) make such other and further payment to Executive, her
      designated beneficiaries and her dependents as may be provided pursuant to
      the
      terms of any employee benefit plans, fringe benefit plans, and all other
      compensation and/bonus plans, programs and structures, in which the Executive
      is
      a participant at the time of termination of her employment with the Company,
      and
      (ii) promptly reimburse the Executive for any then un-reimbursed out-of-pocket
      expenses pursuant to Section 6.

     

    9.6. Confidentiality
      and Proprietary Rights. 
      Executive agrees to continue to abide by the Company’s Information and
      Inventions Agreement.

     

    10.            
      Section
      409A of the U.S. Internal Revenue Code.

     

    10.1.         
      Good
      Faith Intention. 
      The Company and Executive intend in good faith that this Agreement comply with
      the applicable requirements of Section 409A of the Code and that this Agreement
      be construed, interpreted and administered in accordance with such intent. 

     

    11.          
      Attorney’s
      Fees. 
If
      litigation shall be instituted to enforce or interpret any provision of this
      Agreement hereof, the prevailing party will reimburse the other party for
      his/her reasonable attorney’s fees and disbursements incurred in such
      proceeding. 

     

    12.          
      General
      Provisions.

     

    12.1.       
      Successors
      and Assigns. 
      This Agreement shall be binding upon and inure to the benefit of the parties
      hereto and their heirs, personal representatives and successors, including
      any
      successor of the company by reason of any dissolution, merger, consolidation,
      sale of assets or other reorganization of the Company.

     

    12.2.       
      Waiver.
      The
      rights and remedies of the parties to this Agreement are cumulative and not
      alternative.  Neither the failure nor any delay by any party in exercising
      any right, power or privilege under this Agreement or the documents referred
      to
      in this Agreement will operate as a waiver of such right, power or privilege;
      and no single or partial exercise of any such right, power or privilege will
      preclude any other or further exercise of such right, power or privilege or
      the
      exercise of any other right, power or privilege.  To the maximum extent
      permitted by applicable law, (i) no claim or right arising out of this
      Agreement or the documents referred to in this Agreement can be discharged
      by
      one party, in whole or in part, by a waiver or renunciation of the claim or
      right unless in writing signed by the other party; (ii) no waiver that may
      be given by a party will be applicable except in the specific instance for
      which
      it is given; and (iii) no notice to or demand on one party will be deemed
      to be a waiver of any obligation of such party or of the right of the party
      giving such notice or demand to take further action without notice or demand
      as
      provided in this Agreement or the documents referred to in this
      Agreement.

     

    12.3.       
      Validity. 
      The invalidity or unenforceability of any provision or provisions of this
      Agreement shall not affect the validity or enforceability of any other provision
      of this Agreement, which shall remain in full force and effect. 

     

    
      
         

        
        

      

      
        -3-

        
          

        

      

      
        
        

      

    

    124.       
      Headings. 
      The headings set forth in this Agreement are for convenience only and shall
      not
      be used in interpreting this Agreement.  

     

    12.5.       
      Governing
      Law. 
      This Agreement will be governed by and construed in accordance with the laws
      of
      the United States and the State of California,
      without
      reference to its conflicts of laws principles.

     

    12.6.       
      Counterparts. 
      This Agreement may be executed in one or more counterparts, all of which when
      fully executed and delivered by all parties hereto and taken together shall
      constitute a single agreement, binding against each of the parties. 

     

    12.7.       
      Survival. 
      Sections 8, 9, 10, 11 and, 12 of this Agreement shall survive Executive’s
      employment by Company.

     

    12.8. Notices. 
      All notices, consents, waivers and other communications under this Agreement
      shall be in writing and will be deemed to have been duly given when (i)
      delivered by hand (with written confirmation of receipt); (ii) sent by facsimile
      (with written confirmation of receipt); or (iii) when received by the addressee,
      if sent by a nationally recognized overnight delivery service, return

    

    If
      to
      Executive:

    

    Dr.
      Juliet Singh

    P.O.
      Box
      2191

    Rancho
      Santa Fe, CA 92067

    

    If
      to the
      Company:

    

    Dr.
      Jeffrey Abrams

    Member
      of
      the Board of Directors

    Trans-Pharma
      Corporation

    4225
      Executive Square, Suite 460

    La
      Jolla,
      CA 92037

    

    or
      to
      such other address as either party shall have furnished to the other in writing
      in accordance herewith.

     

    [Remainder
      of Page Intentionally Left Blank]

     

    
      
         

        
        

      

      
        -4-

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, THE PARTIES TO THIS AGREEMENT HAVE READ THE FOREGOING AGREEMENT
      AND FULLY UNDERSTAND EACH AND EVERY PROVISION CONTAINED HEREIN. WHEREFORE,
      THE
      PARTIES HAVE EXECUTED THIS AGREEMENT ON THE DATES SHOWN BELOW.

     

    
       

        
          	
                  Dated:
                    

                	
                  June
                    27, 2007

                	 	
                  EXECUTIVE

                
	 	 	 	 
	 	 	 	 
	 	 	 	
                  /s/
                    Juliet Singh, Ph.D.

                
	 	 	 	
                  Dr.
                    Juliet Singh

                
	 	 	 	 
	 	 	 	 
	
                  Dated:
                    

                	
                  June
                    27, 2007

                	 	
                  TRANS-PHARMA
                    CORPORATION.

                
	 	 	 	 
	 	 	 	 
	 	 	 	
                  By:

                	
                  /s/
                    Jeffrey Abrams

                
	 	 	 	 	
                  Name:

                	
                  Dr.
                    Jeffrey Abrams

                
	 	 	 	 	
                  Title:

                	
                  Director

                
	 	 	 	 	 

        

      

    

     

    [Signature
      Page to Employment Agreement]

     

    
      
         

        
        

      

      
        -5-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]